Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
Status:
Not yet recruiting
Trial end date:
2030-08-01
Target enrollment:
Participant gender:
Summary
This is an open label, two-stratum, phase 2 clinical trial evaluating the efficacy of
9-ING-41 in combination with gemcitabine/docetaxel in patients ≥10 years of age with advanced
sarcoma. 9-ING-41 in combination with gemcitabine and docetaxel will lead to sustained
disease control and/or increase the rates of objective response in patients with unresectable
or metastatic soft tissue and bone sarcomas.